XY028-133 |
| Catalog No.GC62701 |
XY028-133 (exemple 14) est un dégradeur de CDK4/6 basé sur PROTAC avec une activité anti-tumorale, qui consiste en des ligands pour von Hippel-Lindau et CDK.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2229974-73-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity[1].
XY028-133 (1 and 3 μM, 24 h) significantly decreases CDK4/6, Cyclin A, PLK1 and pRb protein levels in A375 cells[1].
[1]. JIN, Jian, et al. COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER. Patent. US2017/065027.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *